| Literature DB >> 30766729 |
Binghua Tang1, Shengjie Li1, Wenjun Cao1,2, Xinghuai Sun1,2,3,4,5.
Abstract
PURPOSE: To systematically evaluate the associations between oxidative stress status and different types of glaucoma.Entities:
Year: 2019 PMID: 30766729 PMCID: PMC6350588 DOI: 10.1155/2019/1803619
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1Chart of the article search process.
The level of oxidative stress status with ACG.
| First author | Year | Country | ACG group | Control group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Age (years) | Total antioxidant status | MDA | SOD | GPX | Catalase |
| Age (years) | Total antioxidant status | MDA | SOD | GPX | Catalase | |||
|
| ||||||||||||||||
| Ahmed Mousa | 2015 | Saudi Arabia | 139 | 63.1 ± 9.6 | 0.98 ± 0.41 (mmol/L) | 351 | 61.8 ± 11.7 | 1.1 ± 0.22 (mmol/L) | ||||||||
| Khaled K. Abu-Amero | 2014 | Saudi Arabia | 139 | 63.1 ± 9.4 | 1 ± 0.22 (mmol/L) | 149 | 61.1 ± 10.8 | 0.97 ± 0.43 (mmol/L) | ||||||||
| Dong Chang | 2011 | China | 50 | 59.04 ± 68.42 | 4.35 ± 0.81 (nmol/ml) | 50 | 60.94 ± 6.95 | 3.51 ± 0.84 (nmol/ml) | ||||||||
|
| ||||||||||||||||
| Amita Goyal | 2014 | India | 30 | 44.38 ± 6.47 U/ml | 19.27 ± 3.84 U/ml | 37.09 ± 6.60 fmol/ml | 30 | 21.70 ± 4.93 U/ml | 8.17 ± 2.97 U/ml | 35.57 ± 5.42 fmol/ml | ||||||
ACG: angle-closure glaucoma; MDA: malondialdehyde; SOD: superoxide dismutase; GPX: glutathione peroxidase.
The level of oxidative stress status with OAG.
| First author | Year | Country | OAG group | Control group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Age (years) | Total antioxidant status | Total oxidant status | MDA | SOD | GPX | Catalase |
| Age (years) | Total antioxidant status | Total oxidant status | MDA | SOD | GPX | Catalase | |||
|
| ||||||||||||||||||
| Ugur Yilmaz Mumcu | 2016 | Turkey | 53 | 58.81 ± 12.23 | 1.046 ± 0.84 ( | 52 | 61.53 ± 10.95 | 0.47 ± 0.179 ( | ||||||||||
| Ahmed Mousa | 2015 | Saudi Arabia | 147 | 66.8 ± 17.9 | 0.47 ± 0.32 (mmol/L) | 351 | 61.8 ± 11.7 | 1.1 ± 0.22 (mmol/L) | ||||||||||
| Khaled K. Abu-Amero | 2013 | Saudi Arabia | 139 | 62.3 ± 11.5 | 0.47 ± 0.32 (mmol/L) | 148 | 61.1 ± 10.8 | 0.97 ± 0.43 (mmol/L) | ||||||||||
| O. Awodelo | 2015 | Nigeria | 40 | 57.7 ± 11.2 | 1.28 ± 1.44 (u/mg protein) | 54.8 ± 96.19 (u/mg protein) | 20 | 49.8 ± 20.4 | 1.95 ± 0.76 (u/mg protein) | 56.29 ± 22.01 (u/mg protein) | ||||||||
| Mesut Erdurmuş | 2011 | Turkey | 23 | 62.3 ± 9.0 | 0.6 ± 0.1 mmol/L | 19.6 ± 2.6 | 1.9 ± 0.2 | 13 ± 0.5 mg/L | 19 | 57.4 ± 5.6 | 1.2 ± 0.3 mmol/L | 15.1 ± 7.0 | 1.1 ± 0.2 | 9.4 ± 0.6 mg/L | ||||
|
| ||||||||||||||||||
| Esra Ergan | 2016 | Turkey | 15 | 67.1 ± 9.6 | 2.95 ± 2.0 mmol/L | 31.59 ± 12.7 ( | 31 | 67 ± 9.8 | 1.9 ± 0.79 mmol/L | 28.48 ± 10.08( | ||||||||
| Asaad A. Ghanem | 2010 | Egypt | 30 | 54.5 ± 4.98 | 0.48 ± 0.1 | 39.97 ± 4.82 U/mL | 22.63 ± 2.06 U/mL | 46.77 ± 3.3 fmol/mL | 25 | 51.28 ± 2.82 | 0.06 ± 0.02 | 21.96 ± 1.97 U/mL | 7.72 ± 1.72 U/mL | 46.8 ± 2.2 fmol/mL | ||||
| S.M. Ferreira | 2009 | Argentina | 25 | 70 ± 10 | 42 ± 5 (U/ml) | 16 ± 3 (U/ml) | 42 ± 4 (fmol/ml) | 25 | 73 ± 2 | 27 ± 3 (U/ml) | 6 ± 2 (U/ml) | 38 ± 7(fmol/ml) | ||||||
| Vicente Zanon Moreno | 2008 | Spain | 50 | 70.92 ± 8.19 | 2.818 ± 0.657 mmol/L | 0.471 ± 0.134 mmol/L | 40 | 73.75 ± 6.95 | 4.049 ± 1.577 mmol/L | 0.079 ± 0.028 mmol/L | ||||||||
| Sandra M. Ferreira | 2005 | Argentina | 24 | 71 ± 2 | 52 ± 7 umol/l Trolox | 41.7 ± 2.7 U /ml | 18.4 ± 2.5 U/ml | 42 ± 7 fmol/ml | 24 | 73 ± 2 | 124 ± 5 umol/l Trolox | 26.5 ± 0.5 U /ml | 6.1 ± 0.6 U/ml | 40 ± 7 fmol/ml | ||||
| Amita Goyal | 2014 | India | 30 | 46.19 ± 6.79 U/ml | 20.58 ± 3.18 U/ml | 38.78 ± 6.36 fmol/ml | 30 | 21.70 ± 4.93 U/ml | 8.17 ± 2.97 U/ml | 35.57 ± 5.42 fmol/ml | ||||||||
OAG: open-angle glaucoma; MDA: malondialdehyde; SOD: superoxide dismutase; GPX: glutathione peroxidase.
The level of oxidative stress status with NTG.
| First author | Year | Country | NTG group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Age (years) | Total antioxidant status | Total oxidant status |
| Age (years) | Total antioxidant status | Total oxidant status | |||
|
| ||||||||||
| Necat Yilmaz | 2016 | Turkey | 32 | 59.6 ± 18.7 | 2.2 ± 0.32 | 3(1.3–7.9) ( | 40 | 54.9 ± 12.5 | 2.13 ± 0.24 | 0.95(0.6–1.2)( |
| Kenya Yuki | 2010 | Japan | 43 | 59.0 ± 10.4 | 1.170.6 ± 0.0907 ( | 40 | 62.2 ± 14.5 | 1.113.9 ± 0.1031 (umol/L) | ||
NTG: normal tension glaucoma.
The level of oxidative stress status with EXG.
| First author | Year | Country | EXG group | Control group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Age (years) | Total antioxidant status | Total oxidant status | MDA | SOD | GPX | Catalase |
| Age (years) | Total antioxidant status | Total oxidant status | MDA | SOD | GPX | Catalase | |||
|
| ||||||||||||||||||
| Feyza Dursun | 2015 | Turkey | 26 | 66.19 ± 6.88 | 1.30 ± 0.27mmol/L | 8.57 ± 0.95 | 26 | 67.03 ± 6.34 | 1.52 ± 0.37(mmol/L) | 0.73 ± 0.52 | ||||||||
| Ahmed Mousa | 2015 | Saudi Arabia | 54 | 67.6 ± 10.4 | 0.86 ± 0.24(mmol/L) | 351 | 61.8 ± 11.7 | 1.1 ± 0.22 (mmol/L) | ||||||||||
| Khaled K. Abu-Amero | 2011 | Saudi Arabia | 54 | 67.57 ± 10.43 | 0.866 ± 0.241(mmol/l) | 54 | 67.72 ± 10.60 | 1.07 ± 0.234 (mmol/l) | ||||||||||
| Mesut Erdurmuş | 2011 | Turkey | 24 | 65.7 ± 8.0 | 0.5 ± 0.1mmol/L | 21.2 ± 4.2 | 1.7 ± 0.4 | 11.6 ± 0.2mg/L | 19 | 57.4 ± 5.6 | 1.2 ± 0.3 mmol/L | 15.1 ± 7.0 | 1.1 ± 0.2 | 9.4 ± 0.6 mg/L | ||||
| George G. Koliakos | 2008 | Greece | 20 | 70.9 ± 7.9 | 103 ± 21.4(U/ml) | 20 | 70.8 ± 7.7 | 189.6 ± 84.3 (U/ml) | ||||||||||
| George G. Koliakos | 2009 | Greece | 20 | 71.0 ± 7.5 | 116 ± 38(U/ml) | 20 | 70.8 ± 7.7 | 189.6 ± 84.3 (U/ml) | ||||||||||
| Birsen Can Demirdöğen | 2014 | Turkey | 32 | 70 (67.0–76.0) | 1.90 ± 0.28 (mmol/L) | 20.86 ± 7.54 ( | 32 | 70.5(62.3–78.3) | 2.08 ± 0.35 (mmol Trolox equivalent/L) | 19.96 ± 8.23 ( | ||||||||
| Birsen Can Demirdöğen | 2014 | Turkey | 30 | 72 (64.5–77.8) | 1.88 ± 0.27 (mmol/L) | 22.20 ± 10.35 ( | 32 | 70.5(62.3–78.3) | 2.08 ± 0.35 (mmol Trolox equivalent/L) | 19.96 ± 8.23 ( | ||||||||
| Mehmet Tetikoğlu1 | 2016 | Turkey | 34 | 65.53 ± 9.1 | 28.7 ± 5.7 | 0.12 ± 0.024 (k/ml) | 38 | 62.34 ± 7.7 | 30.4 ± 5.3 | 0.21 ± 0.051 (k/ml) | ||||||||
| Rana Sorkhabi | 2011 | Iran | 27 | 63.89 ± 7.37 | 0.60 ± 0.15 (mmol/L) | 27 | 65.22 ± 9.79 | 0.70 ± 0.14 (mmol/L) | ||||||||||
|
| ||||||||||||||||||
| Esra Ergan | 2016 | Turkey | 15 | 67.1 ± 9.6 | 2.47 ± 0.9 mmol/L) | 31.46 ± 13.2 ( | 31 | 67 ± 9.8 | 1.9 ± 0.79 mmol/L | 28.48 ± 10.08 ( | ||||||||
| Feyza Dursun | 2015 | Turkey | 26 | 67.34 ± 6.93 | 0.80 ± 0.70 mmol/L | 2.79 ± 0.67 umol/L | 26 | 67.03 ± 6.34 | 1.55 ± 0.62 mmol/L | 1.10 ± 0.81 (umol/L) | ||||||||
| Emrullah Beyazyıldız | 2014 | Turkey | 17 | 69.8 ± 8.6 | 2.3 ± 0.7 mmol/L | 57.6 ± 32.4 umol/L | 25 | 68.9 ± 12.0 | 2.5 ± 0.7 mmol/L | 30.4 ± 22.6 umol/L | ||||||||
| S.M. Ferreira | 2009 | Argentina | 25 | 73 ± 2 | 44 ± 7 (U/ml) | 30 ± 2 (U/ml) | 40 ± 5 (fmol/ml) | 25 | 73 ± 2 | 27 ± 3 (U/ml) | 6 ± 2 (U/ml) | 38 ± 7 (fmol/ml) | ||||||
| George G. Koliakos | 2008 | Greece | 20 | 70.9 ± 7.9 | 10.1 ± 4.5 (U/ml) | 20 | 70.8 ± 7.7 | 14.6 ± 1.9 (U/ml) | ||||||||||
| George G. Koliakos | 2009 | Greece | 20 | 71.0 ± 7.5 | 12.2 ± 6 (U/ml) | 20 | 70.8 ± 7.7 | 14.6 ± 1.9 (U/ml) | ||||||||||
| Rana Sorkhabi | 2011 | Iran | 27 | 63.89 ± 7.37 | 0.33 ± 0.13 (mmol/L) | 27 | 65.22 ± 9.79 | 0.34 ± 0.15 (mmol/L) | ||||||||||
EXG: exfoliative glaucoma; MDA: malondialdehyde; SOD: superoxide dismutase; GPX: glutathione peroxidase.
Methodological quality of the studies.
| Name | Sampling scheme | Population characteristics | Data description | Diagnostic criteria | Methods | Score | |||
|---|---|---|---|---|---|---|---|---|---|
| ACG | OAG | NTG | EXG | ||||||
| Ugur Yilmaz Mumcu | Random stratified sample | Adequate | Clear | Clear 1 | HPLC | 5 | |||
| Esra Ergan | Random stratified sample | Adequate | Clear | Clear 2 | Clear 3 | Colorimetric method | 5 | ||
| Necat Yilmaz | Random stratified sample | Adequate | Clear | Clear 4 | Clear 5 | Colorimetric measurement method | 5 | ||
| Feyza Dursun | Random stratified sample | Adequate | Clear | No | Colorimetric method | 4 | |||
| Ahmed Mousa | Random stratified sample | Adequate | Clear | European Glaucoma Society guidelines | European Glaucoma Society guidelines | European glaucoma society guidelines | Colorimetric-based assay | 5 | |
| Emrullah Beyazyıldız | Random stratified sample | Adequate | Clear | No | Colorimetric-based assay | 4 | |||
| Khaled K. Abu-Amero | Random stratified sample | Adequate | Clear | Clear 6 | Colorimetric method | 5 | |||
| Khaled K. Abu-Amero | Random stratified sample | Adequate | Clear | Clear 7 | Colorimetric-based assay | 5 | |||
| O. Awodelo | Random stratified sample | Adequate | Clear | No | Spectrophotometric method | 4 | |||
| Dong Chang | Random stratified sample | Adequate | Clear | Clear 8 | Thiobarbituric acid-reacting substance (TBARS) production | 5 | |||
| Khaled K. Abu-Amero | Random stratified sample | Adequate | Clear | Clear 9 | Colorimetric-based assay | 5 | |||
| Mesut Erdurmuş | Random stratified sample | Adequate | Clear | Clear 10 | Clear 11 | Clear | 5 | ||
| Kenya Yuki | Random stratified sample | Adequate | Clear | Clear 12 | Colorimetric method | 5 | |||
| Asaad A. Ghanem | Random stratified sample | Adequate | Clear | Clear 13 | Thiobarbituric acid reaction/spectrophotometry | 5 | |||
| S.M. Ferreira | Random stratified sample | Adequate | Clear | Clear 14 | Clear 15 | Spectrophotometrically | 5 | ||
| George G. Koliakos | Random stratified sample | Adequate | Clear | No | Colorimetric method | 4 | |||
| Vicente Zanon Moreno | Random stratified sample | Adequate | Clear | No | Colorimetric technique | 4 | |||
| S.M. Ferreira | Random stratified sample | Adequate | Clear | Clear 16 | Chemiluminescence/spectrophotometrically | 5 | |||
| Birsen Can Demirdöğen | Random stratified sample | Adequate | Clear | Clear 17 | Colorimetric method | 5 | |||
| Mehmet Tetikoğlu1 | Random stratified sample | Adequate | Clear | Clear 18 | Enzymatic analysis | 5 | |||
| Amita Goyal | Random stratified sample | Adequate | Clear | No | No | Spectrophotometrically | 4 | ||
| Rana Sorkhabi | Random stratified sample | Adequate | Clear | Clear 19 | Spectrophotometric assay | 5 | |||
EXG: exfoliative glaucoma; NTG: normal tension glaucoma; OAG: open-angle glaucoma; ACG: angle-closure glaucoma. Clear: (1) we described POAG patients who have intraocular pressure (IOP) higher than 21 mmHg, cup/disk rate 0.3, retinal nerve fiber layer defects in OCT, and visual field defects. (2) Patients >45 years old were diagnosed with PEG if they showed typical pseudoexfoliation material on the lens and/or papillary border with an IOP ≥22 mmHg, cup-to-disc ratio ≥0.3, generalized or partial rim notching on the optic nerve head, peripapillary choroidal atrophy or splinter hemorrhage, and glaucomatous visual field damage according to the Advanced Glaucoma Intervention Study score. Patients with all of these findings, except PEM, were diagnosed with POAG. (3) Patients >45 years old were diagnosed with PEG if they showed typical pseudoexfoliation material (PEM) on the lens and/or papillary border with an IOP ≥22 mmHg, cup-to-disc ratio ≥0.3, generalized or partial rim notching on the optic nerve head, peripapillary choroidal atrophy or splinter hemorrhage, and glaucomatous visual field damage according to the Advanced Glaucoma Intervention Study score. Patients with all of these findings, except PEM, were diagnosed with POAG. (4) Patients with an IOP of 21 mmHg or lower, displaying glaucomatous changes in the optic disc (atrophy, neuroretinal rim loss, and peripapillary hemorrhage) and in the visual field were diagnosed as having NTG. (5) A diagnosis of PEXG was given if the results for the anterior segment of the pseudoexfoliative component showed an IOP exceeding 21 mmHg without typical optic nerve head changes or visual field effects. (6) At least three of the following: (i) clinical documentation of angle closure, defined as the presence of appositional or synnechial closure of the anterior chamber angle involving at least 270° by gonioscopy in either eye; (ii) intraocular pressure elevated to a level ≥21 mmHg measured by Goldmann applanation tonometry; (iii) evidence of characteristic glaucomatous optic disk damage with excavation of the disc causing a cup-to-disk ratio (c/d) vertically of at least 0.70 in at least one eye; and (iv) characteristic peripheral visual field loss including nerve fiber bundle defects (nasal step, arcuate scotoma, and paracentral scotoma) or advanced visual field loss (central and/or temporal island of vision) as tested by using an Humphrey Field analyzer in those patients with vision better than 20/200 or Goldmann Manual perimetry in those with worse vision. (7) (i) appearance of the disc or retinal nerve fiber layer, e.g., thinning or notching of disc rim, progressive changes, nerve fiber layer defect; (ii) the presence of characteristic abnormalities in visual field (e.g., arcuate scotoma, nasal step, paracentral scotoma, and generalized depression) in the absence of other causes or explanation; (iii) age greater than 40 years at the time of recruitment, and (iv) open anterior chamber angles bilaterally on gonioscopy. (8) The diagnostic criteria for PACG were as follows: open and nonoccludable anterior chamber angles with gonioscopy (Volk 3 Mirror Gonio Lens, Mentor, USA), glaucomatous optic disc cupping was identified as a vertical cup-to-disc ratio of optic nerve head 0.6 or more, difference of the vertical cup-to-disc ratio 0.2 or more between both eyes, rim width at superior portion (11–1 h) or inferior portion (5–7 h) of 0.2 or less of disc diameter, or the presence of nerve fiber layer defect. (9) Subjects with PEG were defined as those with clinical evidence of exfoliation material on the pupil margin or anterior lens surface, the presence of glaucomatous optic neuropathy with associated visual field loss in one or both eyes, and documented IOP ≥22 mmHg in either eye. (10) POAG was defined as a progressive optic neuropathy characterized by specific glaucomatous optic nerve head damage and visual field loss associated with elevated IOP. (11) A presence of PEX in PEG is confirmed clinically by small, white deposits of material in the anterior segment, most commonly on the pupillary border and anterior lens capsule. (12) After the diagnosis of primary open-angle glaucoma was made, each patient's IOP was measured at seven time-points over 24 hr (i.e., at 6, 9, 12, 15, 18, 21, and 24 o'clock) with Goldmann applanation tonometry, to identify the patients with normal tension glaucoma. (13) POAG patients with elevated intraocular pressure, correlated visual field loss, and glaucomatous optic nerve head changes criteria. (14) Glaucoma patients included in the study had a diagnosis of POAG or XFG. Structural definition: vertical cup-to-disc ratios (C/D) of 0.7 or more, asymmetry in the C/D of 0.2 or more, and/or thinning of the neuroretinal rim-to-disc ratio of less than 0.1 with corresponding perimetric damage. The Disc Damage Likelihood Scale system was used to evaluate the rim-to-disc ratio. Functional definition: the glaucoma hemifield test outside normal limits, and three adjacent points in the 5% level on the pattern deviation plot, using the 24–2 strategy of the Humphrey perimeter. Visual fields were considered reliable if false-negative and false-positive responses were below 33%. Unreliable visual fields were repeated on the same day. If the second visual field was also unreliable, inclusion was made only on the basis of structural damage. (15) For the diagnosis of XFS, only the presence of the material in the anterior surface of the lens was considered. This surface, with the pupil dilated, was carefully examined for the presence of exfoliative material, using the high magnification of the slit-lamp and adequate illumination. (16) Angles were wide open on gonioscopy. Vertical cup/disk ratio ranged from 0.80 to 0.99, showing severe glaucomatous optic nerve damage. (17) The diagnosis of PEX was made on slit-lamp examination following mydriasis and included the presence of typical pseudoexfoliation material on the anterior lens capsule and/or the pupillary border. PG patients were diagnosed when anterior segment findings of PEX accompanied an IOP > 21 mmHg without treatment, typical optic nerve head changes, and visual field defects. (18) The diagnosis of PEX syndrome was made using a slit-lamp examination after pupillary dilation according to the presence of PEX material on the anterior lens capsule and/or on the pupillary border. (19) PEX syndrome was diagnosed if clinical examination revealed deposition of PEX material on the anterior lens capsule or at the pupillary border, the presence of transillumination defects near the pupil accompanied by normal optic nerve head finding, and intraocular pressure (IOP) less than 21 mmHg.
Figure 2The meta-analysis of blood TAS levels in the OAG group.
Figure 3The meta-analysis of aqueous humor SOD levels in the OAG group.
Figure 4The meta-analysis of aqueous humor GPX levels in the OAG group.
Figure 5The meta-analysis of aqueous humor CAT levels in the OAG group.
Figure 6The meta-analysis of blood TAS levels in the EXG group.
Figure 7The meta-analysis of blood TOS levels in the EXG group.
Figure 8The meta-analysis of aqueous humor TAS levels in the EXG group.
Figure 9The meta-analysis of aqueous humor TAS levels in the EXG group.
Sensitivity analysis using the leave-one-out strategy.
| Study omitted | Sample |
| 95% CI |
|
|---|---|---|---|---|
| OAG (total antioxidant status) | Blood | |||
| Ahmed Mousa (2015) | 11.084 | −0.633 to −0.433 | <0.001 | |
| Khaled K. Abu-Amero (2013) | 26.848 | −0.672 to −0.581 | <0.001 | |
| Mesut Erdurmus (2011) | 8.806 | −0.697 to −0.443 | <0.001 | |
| OAG (SOD) | Aqueous humor | |||
| Asaad A. Ghanem (2010) | 5.050 | 3.059 to 7.021 | <0.001 | |
| S.M. Ferreira (2009) | 5.883 | 3.620 to 7.236 | <0.001 | |
| Sandra M. Ferreira (2005) | 13.455 | 3.526 to 4.728 | <0.001 | |
| Amita Goyal (2014) | 5.073 | 3.242 to 6.293 | <0.001 | |
| OAG (GPX) | Aqueous humor | |||
| Asaad A. Ghanem (2010) | 15.206 | 10.097 to 13.085 | <0.001 | |
| S.M. Ferreira (2009) | 14.255 | 11.422 to 15.064 | <0.001 | |
| Sandra M. Ferreira (2005) | 8.121 | 9.460 to 15.480 | <0.001 | |
| Amita Goyal (2014) | 9.213 | 9.793 to 15.086 | <0.001 | |
| OAG (catalase) | Aqueous humor | |||
| Asaad A. Ghanem (2010) | 3.311 | 1.313 to 5.122 | 0.001 | |
| S.M. Ferreira (2009) | 1.187 | −0.504 to 2.054 | 0.235 | |
| Sandra M. Ferreira (2005) | 1.818 | −0.090 to 2.396 | 0.069 | |
| Amita Goyal (2014) | 1.304 | −0.433 to 2.151 | 0.192 | |
| EXG (total antioxidant status) | Blood | |||
| Feyza Dursun (2015) | 3.623 | −0.414 to −0.123 | <0.001 | |
| Ahmed Mousa (2015) | 3.002 | −0.441 to −0.093 | 0.003 | |
| Khaled K. Abu-Amero (2011) | 3.338 | −0.433 to −0.113 | 0.001 | |
| Mesut Erdurmus (2011) | 6.924 | −0.241 to −0.135 | <0.001 | |
| Birsen Can Demirdogen (2014) | 3.678 | −0.422 to −0.128 | <0.001 | |
| Birsen Can Demirdogen (2014) | 3.630 | −0.419 to −0.125 | <0.001 | |
| Rana Sorkhabi (2011) | 3.960 | −0.438 to −0.145 | <0.001 | |
| EXG (total oxidant status) | Blood | |||
| Feyza Dursun (2015) | 1.918 | −0.072 to 6.578 | 0.055 | |
| Mesut Erdurmus (2011) | 1.497 | −1.228 to 9.174 | 0.134 | |
| Birsen Can Demirdogen (2014) | 1.130 | 0.209 to 9.006 | 0.236 | |
| Birsen Can Demirdogen (2014) | 2.696 | 1.448 to 9.162 | 0.007 | |
| EXG (total antioxidant status) | Aqueous humor | |||
| Esra Ergan (2016) | 1.255 | −0.773 to 0.169 | 0.209 | |
| Feyza Dursun (2015) | 0.426 | −0.256 to 0.398 | 0.670 | |
| Emrullah Beyazyildiz (2014) | 0.292 | −0.657 to 0.487 | 0.770 | |
| Rana Sorkhabi (2011) | 0.387 | −0.876 to 0.87 | 0.699 | |
| EXG (total oxidant status) | Aqueous humor | |||
| Esra Ergan (2016) | 1.029 | −11.808 to 37.886 | 0.304 | |
| Feyza Dursun (2015) | 1.151 | −9.750 to 37.476 | 0.250 | |
| Emrullah Beyazyildiz (2014) | 8.233 | 1.291 to 2.098 | <0.001 |
OAG: open-angle glaucoma; EXG: exfoliative glaucoma; SOD: superoxide dismutase; GPX: glutathione peroxidase; CI = confidence interval. The influenced meta-analysis results regarding the association of oxidative stress with OAG and EXG.